Al­ler­gan gets a win: FDA ap­proves ubro­gepant as cas­cade of treat­ments re­shape mi­graine field

Two weeks af­ter pub­lish­ing suc­cess­ful Phase III tri­al da­ta in the New Eng­land Jour­nal of Med­i­cine, Al­ler­gan has land­ed ap­proval for their new acute mi­graine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER